U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | Contact Us | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages

Start Over | Back to Previous Screen

Remifentanil Injection
Status: Currently in Shortage
»Date first posted: 06/28/2022
»Therapeutic Categories: Analgesia/Addiction

Expand all

Fresenius Kabi USA (Revised 11/14/2022)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
1 mg per vial, SDV (NDC 63323-723-03) Backordered. Next release November 2022. Check wholesaler inventory Demand increase for the drug
2 mg per vial, SDV (NDC 63323-724-05) Backordered. Next release November 2022. Check wholesaler inventory Demand increase for the drug
5 mg per vial, SDV (NDC 63323-725-10) Available Check wholesaler inventory Demand increase for the drug

Hikma Pharmaceuticals (Revised 08/26/2022)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
1 mg/vial (NDC 0143-9391-10) This presentation is on backorder. Product will be available September 2022 Demand increase for the drug
2 mg/Vial (NDC 0143-9392-10) This presentation is on backorder. Product will be available September 2022 Demand increase for the drug
5 mg/mL (NDC 0143-9393-10) Currently available Demand increase for the drug

Mylan, a Viatris Company (Reverified 11/23/2022)

Company Contact Information:
800-796-9526

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
1 mg (NDC 67457-198-03) Unavailable Re-supply in November 2022. Demand increase for the drug
2 mg (NDC 67457-198-05) Unavailable Re-supply in January 2023. Demand increase for the drug
5 mg (NDC 67457-198-10) Unavailable Re-supply in February 2023. Demand increase for the drug
Back to Top